Citations (152)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (33)
Ryan W Jacobs, Farrukh T Awan, Lori A Leslie, Saad Z Usmani & Nilanjan Ghosh. (2016) The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. Expert Review of Hematology 9:12, pages 1177-1187.
Read now
Read now
Anders Österborg, Miklós Udvardy, Andrey Zaritskey, Per-Ola Andersson, Sebastian Grosicki, Grzegorz Mazur, Polina Kaplan, Michael Steurer, Anna Schuh, Marco Montillo, Iryna Kryachok, Jan Moritz Middeke, Yaroslav Kulyaba, Grygoriy Rekhtman, Michele Gorczyca, Siobhan Daly, Chai-Ni Chang, Steen Lisby & Ira Gupta. (2016) Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 57:9, pages 2037-2046.
Read now
Read now
Clemens M. Wendtner, Michael Hallek, Graeme A. M. Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Dürig, Matt Kalaycio, John G. Gribben, Stephan Stilgenbauer, Andreas Buhler, Thomas J. Kipps, Brendan Purse, Jennie Zhang, Sabine De Bedout, Jay Mei & Asher Chanan-Khan. (2016) Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leukemia & Lymphoma 57:6, pages 1291-1299.
Read now
Read now
Anna Maria Frustaci, Alessandra Tedeschi, Paola Picardi, Roberto Cairoli & Marco Montillo. (2015) Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. Biologics: Targets and Therapy 9, pages 75-86.
Read now
Read now
Sandra Eketorp Sylvan, Lotta Hansson, Claes Karlsson, Stefan Norin, Jeanette Lundin & Anders Österborg. (2014) Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. Leukemia & Lymphoma 55:8, pages 1774-1780.
Read now
Read now
Julie Elizabeth Chang & Brad Steven Kahl. (2012)
Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 13:10, pages 1495-1505.
Read now
Read now
Lukáš Smolej. (2012) The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 21:7, pages 1009-1017.
Read now
Read now
Stéphane Lepretre, Uli Jäger, Ann Janssens, Veronique Leblond, Eugene Nikitin, Tadeusz Robak & Clemens-Martin Wendtner. (2012) The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. Leukemia & Lymphoma 53:5, pages 820-829.
Read now
Read now
Clemens-Martin Wendtner, Peter Hillmen, Daruka Mahadevan, Andreas Bühler, Lutz Uharek, Steven Coutré, Olga Frankfurt, Adrian Bloor, Francesc Bosch, Richard R. Furman, Eva Kimby, John G. Gribben, Marco Gobbi, Luke Dreisbach, David D. Hurd, Mikkael A. Sekeres, Alessandra Ferrajoli, Sheetal Shah, Jennie Zhang, Laure Moutouh-de Parseval, Michael Hallek, Nyla A. Heerema, Stephan Stilgenbauer & Asher A. Chanan-Khan. (2012) Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 53:3, pages 417-423.
Read now
Read now
Ali Bazargan, Constantine S Tam & Michael J Keating. (2012) Predicting survival in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 12:3, pages 393-403.
Read now
Read now
Mark C. Lanasa, Patricia H. Davis, Michael Datto, Zhiguo Li, Jon P. Gockerman, Joseph O. Moore, Carlos M. DeCastro, Daphne R. Friedman, Louis F. Diehl, Catherine Rehder, Harry Cook, F. Joseph Daugherty, Karen M. B. Matta, J. Brice Weinberg & David Rizzieri. (2012) Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leukemia & Lymphoma 53:2, pages 218-224.
Read now
Read now
Regina Pileckyte, Mindaugas Jurgutis, Vilma Valceckiene, Mindaugas Stoskus, Egle Gineikiene, Jurgita Sejoniene, Andrius Degulys, Tadas Zvirblis & Laimonas Griskevicius. (2011) Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leukemia & Lymphoma 52:6, pages 1055-1065.
Read now
Read now
Leslie A Andritsos & Michael R Grever. (2011) Salvage therapy for relapsed chronic lymphocytic leukemia. Expert Review of Hematology 4:2, pages 199-212.
Read now
Read now
Pau Abrisqueta, Marta Crespo & Francesc Bosch. (2011) Personalizing treatment for chronic lymphocytic leukemia. Expert Review of Hematology 4:1, pages 27-35.
Read now
Read now
Carmen Diana Schweighofer & Clemens-Martin Wendtner. (2010) First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. OncoTargets and Therapy 3, pages 53-67.
Read now
Read now
Ali Bazargan & Constantine S. Tam. (2010) New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents. Leukemia & Lymphoma 51:9, pages 1596-1611.
Read now
Read now
Apostolia-Maria Tsimberidou & Michael J. Keating. (2010) Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. Leukemia & Lymphoma 51:7, pages 1188-1199.
Read now
Read now
Anders Österborg. (2010) Ofatumumab, a human anti-CD20 monoclonal antibody. Expert Opinion on Biological Therapy 10:3, pages 439-449.
Read now
Read now
Alessandro Isidori & Giuseppe Visani. (2009) The prevention of alemtuzumab-induced cytomegalovirus reactivation: still a matter of debate. An update from Pesaro experience with once weekly intravenous ganciclovir. Leukemia & Lymphoma 50:2, pages 294-296.
Read now
Read now
Marco Montillo, Francesca Ricci, Sara Miqueleiz, Alessandra Tedeschi & Enrica Morra. (2008) Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL). Biologics: Targets and Therapy 2:1, pages 41-52.
Read now
Read now
Anke Kretz-Rommel & Katherine S Bowdish. (2008) Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. Expert Opinion on Biological Therapy 8:1, pages 5-15.
Read now
Read now
Vu Nguyen & Koen van Besien. (2008) Late relapse following allogeneic transplant for chronic lymphocytic leukemia: How good are graft versus leukemia effects?. Leukemia & Lymphoma 49:9, pages 1651-1652.
Read now
Read now
David Hui, Wendy Lam, Cynthia Toze, Michael Delorme, Michael Noble, Paul Klimo, Judy Sutherland, Karamjit Gill, Joseph Connors & Laurie Sehn. (2008) Alemtuzumab in clinical practice: A British Columbia experience. Leukemia & Lymphoma 49:2, pages 218-226.
Read now
Read now
Constantine S. Tam, Susan O'Brien, Susan Lerner, I. Khouri, A. Ferrajoli, S. Faderl, M. Browning, Apostolia M. Tsimberidou, Hagop Kantarjian & William G. Wierda. (2007) The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leukemia & Lymphoma 48:10, pages 1931-1939.
Read now
Read now
Thomas Elter, Michael Hallek & Andreas Engert. (2006) Fludarabine in chronic lymphocytic leukaemia. Expert Opinion on Pharmacotherapy 7:12, pages 1641-1651.
Read now
Read now
Karen WL Yee & Susan M O’Brien. (2006) Emerging drugs for chronic lymphocytic leukaemia. Expert Opinion on Emerging Drugs 11:1, pages 167-189.
Read now
Read now
Giuseppe Visani, Anna Mele, Barbara Guiducci, Francesca D'adamo, Giuliana Leopardi, Sara Barulli, Lara Malerba, Moira Lucesole, Giovanni Sparaventi, Pier Paolo Piccaluga, Elena Guernaccini, Fabrizio Agostinelli & Alessandro Isidori. (2006) An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. Leukemia & Lymphoma 47:12, pages 2542-2546.
Read now
Read now
Farhad Ravandi & Susan O'Brien. (2006) Alemtuzumab in CLL and Other Lymphoid Neoplasms. Cancer Investigation 24:7, pages 718-725.
Read now
Read now
Edgardo S Santos, Mohamad Masri & Hana Safah. (2005) Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 5:5, pages 875-891.
Read now
Read now
Farhad Ravandi & Susan O’Brien. (2005) Alemtuzumab. Expert Review of Anticancer Therapy 5:1, pages 39-51.
Read now
Read now
R. Herbrecht, A. Moghaddam, L. Mahmal, S. Natarajan-Ame, L.-M. Fornecker & V. Letscher-Bru. (2005) Invasive aspergillosis in the hematologic and immunologic patient: new findings and key questions in leukemia. Medical Mycology 43:sup1, pages 239-242.
Read now
Read now
Imran Haider & Mary Cahill. (2004) Fatal Thrombocytopaenia Temporally Related to the Administration of Alemtuzumab (MabCampath) for Refractory CLL Despite Early Discontinuation of Therapy. Hematology 9:5-6, pages 409-411.
Read now
Read now
Articles from other publishers (119)
Constantine S. Tam. (2021) Upfront therapy: the case for continuous treatment. Hematology 2021:1, pages 55-58.
Crossref
Crossref
Marisa J. L. Aitken, Hun J. Lee & Sean M. Post. (2019) Emerging treatment options for patients with p53-pathway-deficient CLL. Therapeutic Advances in Hematology 10, pages 204062071989135.
Crossref
Crossref
Martin Šimkovič, Monika Motyčková, Pavel Vodárek & Lukáš Smolej. (2017) Treatment of elderly and comorbid patients with chronic lymphocytic leukemia. Onkologie 11:3, pages 108-114.
Crossref
Crossref
C.S. Tam & J.F. Seymour. (2017) Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?. Annals of Oncology 28:5, pages 920-921.
Crossref
Crossref
E.A. Nikitin, E.A. Dmitrieva, M.A. Panteleev, E.L. Emelina, V.L. Ivanova, Yu.B. Kochkareva, E.G. Arshanskaya, I.E. Lazarev, E.E. Markova, L.A. Mukha, N.G. Novitskaya, M.M. Pankrashkina, V.V. Glazunova, A.V. Shubina, S.A. Chernysh, N.K. Khuazheva, E.V. Naumova, S.A. Lugovskaya, M.E. Pochtar', T.N. Obukhova, O.Yu. Vinogradova, G.E. Gendlin & V.V. Ptushkin. (2017) Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia. Clinical oncohematology 10:3, pages 271-281.
Crossref
Crossref
Yu Zhou & James D. Marks. 2016. Biosimilars of Monoclonal Antibodies. Biosimilars of Monoclonal Antibodies
85
111
.
Julio C. Chavez, Miguel Piris-Villaespesa, Samir Dalia, John Powers, Elyce Turba, Lisa Nodzon, Rami Komrokji, Lubomir Sokol, Frederick L. Locke, Jeffrey Lancet, Eduardo M. Sotomayor, Mohamed A. Kharfan-Dabaja & Javier Pinilla-Ibarz. (2016) Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leukemia Research 47, pages 78-83.
Crossref
Crossref
Julie E. Chang, Thomas Havighurst, KyungMann Kim, Jens Eickhoff, Anne M. Traynor, Rachel Kirby-Slimp, Lynn M. Volk, Jae Werndli, Ronald S. Go, Matthias Weiss, Jules Blank & Brad S. Kahl. (2016) Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. British Journal of Haematology 173:2, pages 283-291.
Crossref
Crossref
Esmeralda Chi-yuan Teo, Yveline Chew & Colin Phipps. (2016) A review of monoclonal antibody therapies in lymphoma. Critical Reviews in Oncology/Hematology 97, pages 72-84.
Crossref
Crossref
Susan M. O'BrienNicole LamannaThomas J. KippsIan FlinnAndrew D. ZelenetzJan A. BurgerMichael KeatingSiddhartha Mitra, Leanne Holes, Albert S. Yu, David M. Johnson, Langdon L. Miller, Yeonhee Kim, Roger D. Dansey, Ronald L. Dubowy & Steven E. Coutre. (2015) A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood 126:25, pages 2686-2694.
Crossref
Crossref
Mariarita Sciumè, Daniele Vincenti, Gianluigi Reda, Nicola Orofino, Ramona Cassin, Diana Giannarelli, Gianluca Gaidano, Davide Rossi & Agostino Cortelezzi. (2015) Low‐dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long‐term outcome from a single center experience. American Journal of Hematology 90:11, pages 970-974.
Crossref
Crossref
Romain GuièzePauline RobbeRuth CliffordSophie de GuibertBruno PereiraAdele TimbsMarie-Sarah DilhuydyMaite CabesLoïc YsebaertAdam BurnsFlorence Nguyen-KhacFrédéric DaviLauren VéronèsePatricia CombesMagali Le Garff-TavernierVéronique LeblondHélène Merle-BéralReem AlsolamiAngela HamblinJoanne MasonAndrew PettittPeter Hillmen, Jenny Taylor, Samantha J. L. Knight, Olivier TournilhacAnna Schuh. (2015) Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood 126:18, pages 2110-2117.
Crossref
Crossref
Aaron C. Logan & David B. Miklos. 2015. Thomas’ Hematopoietic Cell Transplantation. Thomas’ Hematopoietic Cell Transplantation
714
726
.
Eric Durot, Anne-Sophie Michallet, Stéphane Leprêtre, Quoc-Hung Le, Véronique Leblond & Alain Delmer. (2015) Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. European Journal of Haematology 95:2, pages 160-167.
Crossref
Crossref
Taehwan Park, Scott K. Griggs & Dong-Churl Suh. (2015) Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review. BioDrugs 29:4, pages 259-274.
Crossref
Crossref
Anders Österborg, William G. Wierda, Jiří Mayer, Georg Hess, Peter Hillmen, Johannes Schetelig, Anna Schuh, Lukáš Smolej, Christian Beck, Brigitte Dreyfus, Andrzej Hellman, Piotr Kozlowski, Michael Pfreundschuh, Rita Rizzi, Martin Spacek, Jennifer L. Phillips, Ira V. Gupta, Vanessa Williams, Roxanne C. Jewell, Noelia Nebot, Steen Lisby & Martin J. S. Dyer. (2015) Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. British Journal of Haematology 170:1, pages 40-49.
Crossref
Crossref
Carlos Cuesta-Mateos, Javier Loscertales, Anna Kreutzman, Beatriz Colom-Fernández, Itxaso Portero-Sáinz, Juan José Pérez-Villar, Fernando Terrón & Cecilia Muñoz-Calleja. (2015) Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy 64:6, pages 665-676.
Crossref
Crossref
Naoki Shimada, Koichiro Yuji, Nobuhiro Ohno, Tomohiko Koibuchi, Naoki Oyaizu, Kaoru Uchimaru & Arinobu Tojo. (2015)
Treatment of chronic lymphocytic leukemia with bendamustine in an
HIV
‐infected patient on antiretroviral therapy: a case report and review of the literature
. Clinical Case Reports 3:6, pages 453-460.
Crossref
Crossref
Mark C. Lanasa, Leslie Andritsos, Jennifer R. Brown, Janice Gabrilove, Federico Caligaris-Cappio, Paolo Ghia, Richard A. Larson, Thomas J. Kipps, Veronique Leblond, Donald W. Milligan, Ann Janssens, Amy J. Johnson, Nyla A. Heerema, Andreas Bühler, Stephan Stilgenbauer, Jeanne Devin, Michael Hallek, John C. Byrd & Michael R. Grever. (2015) Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia Research 39:5, pages 495-500.
Crossref
Crossref
Javier Pinilla-Ibarz & Julio C. Chavez. (2015) Life after ibrutinib? A new unmet need in CLL. Blood 125:13, pages 2013-2014.
Crossref
Crossref
J E Castro, M Y Choi, T Carvajal, E Almahasnah, J Chang, D F James & T J Kipps. (2014) Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. Blood Cancer Journal 4:11, pages e258-e258.
Crossref
Crossref
Thomas Elter, Michael Hallek & Janice M. Reichert. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1323
1374
.
Ronald M. Sobecks, Jose F. Leis, Robert Peter Gale, Kwang Woo Ahn, Xiaochun Zhu, Mitchell Sabloff, Marcos de Lima, Jennifer R. Brown, Yoshihiro Inamoto, Gregory A. Hale, Mahmoud D. Aljurf, Rammurti T. Kamble, Jack W. Hsu, Steven Z. Pavletic, Baldeep Wirk, Matthew D. Seftel, Ian D. Lewis, Edwin P. Alyea, Jorge Cortes, Matt E. Kalaycio, Richard T. Maziarz & Wael Saber. (2014) Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens. Biology of Blood and Marrow Transplantation 20:9, pages 1390-1398.
Crossref
Crossref
Rohtesh S. Mehta, Antonio Di Stasi, Chitra Hosing, Nina Shah, Katayoun Rezvani, Amin Alousi, Susan O'Brien, William Wierda, Michael Keating & Elizabeth J. Shpall. (2014) Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. Clinical Lymphoma Myeloma and Leukemia 14:3, pages e105-e109.
Crossref
Crossref
A Cortelezzi, M Sciumè, A M Liberati, D Vincenti, A Cuneo, G Reda, L Laurenti, F Zaja, R Marasca, A Chiarenza, G Gritti, L Orsucci, S Storti, E Angelucci, N Cascavilla, M Gobbi, F R Mauro, F Morabito, S Fabris, A Piciocchi, M Vignetti, A Neri, D Rossi, D Giannarelli, A Guarini & R Foà. (2013) Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia 28:3, pages 642-648.
Crossref
Crossref
Mitchell Sabloff, Ronald M. Sobecks, Kwang Woo Ahn, Xiaochun Zhu, Marcos de Lima, Jennifer R. Brown, Yoshihiro Inamoto, H. Kent Holland, Mahmoud D. Aljurf, Mary J. Laughlin, Rammurti T. Kamble, Jack W. Hsu, Baldeep M. Wirk, Matthew Seftel, Ian D. Lewis, Mukta Arora, Edwin P. Alyea, Matt E. Kalaycio, Jorge Cortes, Richard T. Maziarz, Robert Peter Gale & Wael Saber. (2014) Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen–Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?. Biology of Blood and Marrow Transplantation 20:3, pages 421-424.
Crossref
Crossref
Julie E. Chang & Brad S. Kahl. (2014) PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports 9:1, pages 33-43.
Crossref
Crossref
Huayuan Zhu, Wei Wu, Yuan Fu, Wenyi Shen, Kourong Miao, Min Hong, Wei Xu, Ken H. Young, Peng Liu & Jianyong Li. (2013) Overexpressed BAG3 is a potential therapeutic target in chronic lymphocytic leukemia. Annals of Hematology 93:3, pages 425-435.
Crossref
Crossref
Arnon P. Kater, Marjolein Spiering, Roberto D. Liu, G. Doreen te Raa, E. Slinger, Sanne H. Tonino, Marielle M. Beckers, Simon Daenen, Jeanette K. Doorduijn, Nienke A.G. Lankheet, Dieuwertje M. Luijks, Eric Eldering & Marinus H.J. van Oers. (2014) Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study. Leukemia Research 38:1, pages 34-41.
Crossref
Crossref
Kirsty Cuthill & Stephen Devereux. (2013) How I treat patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology 163:4, pages 423-435.
Crossref
Crossref
J-Y Yoon, D Szwajcer, G Ishdorj, P Benjaminson, W Xiao, R Kumar, J B Johnston & S B Gibson. (2013) Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B. Blood Cancer Journal 3:10, pages e153-e153.
Crossref
Crossref
Andrea SchnaiterPeter PaschkaMarianna RossiThorsten ZenzAndreas BühlerDirk WinklerMario CazzolaKonstanze DöhnerJennifer EdelmannDaniel MertensSabrina KlessSilja MackRaymonde Busch, Michael Hallek, Hartmut DöhnerStephan Stilgenbauer. (2013) NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 122:7, pages 1266-1270.
Crossref
Crossref
Jacques-Olivier Bay, Romain Guièze, Aurélie Ravinet, Richard Lemal, Aliénor Xhaard, Sébastien Bailly, Cécile Moluçon-Chabrot, Éric Hermet, Julian Biau, Pierre Verrelle, Régis Peffault de Latour & Olivier Tournilhac. (2013) Avancées thérapeutiques majeures et nouvelles perspectives en onco-hématologie. Bulletin du Cancer 100:6, pages 587-599.
Crossref
Crossref
April D. Sorrell, Carin R. Espenschied, Julie O. Culver & Jeffrey N. Weitzel. (2013) Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome. Molecular Diagnosis & Therapy 17:1, pages 31-47.
Crossref
Crossref
Eleonora Fonte, Benedetta Apollonio, Lydia Scarfò, Pamela Ranghetti, Claudia Fazi, Paolo Ghia, Federico Caligaris-Cappio & Marta Muzio. (2013)
In Vitro
Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
. Clinical Cancer Research 19:2, pages 367-379.
Crossref
Crossref
Romain Guièze, Loïc Ysebaert, Sophie de Guibert, Nathalie Dhédin, Jacques-Oliver Bay, Xavier Troussard & Olivier Tournilhac. (2012) Stratégies classiques de traitement des rechutes de leucémie lymphoïde chronique. Bulletin du Cancer 99:12, pages 1123-1132.
Crossref
Crossref
Jolanta D. Żołnierczyk, Oxana Komina, Jerzy Z. Błoński, Arleta Borowiak, Barbara Cebula-Obrzut, Piotr Smolewski, Paweł Robak, Zofia M. Kiliańska & Józefa Węsierska-Gądek. (2011) Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment. Medical Oncology 29:3, pages 2111-2126.
Crossref
Crossref
Michael J Keating & Constantine TamDavid G Maloney. 2012. Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia. Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia
54
64
.
Marays VelizJavier Pinilla-Ibarz. (2012) Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia. Cancer Control 19:1, pages 37-53.
Crossref
Crossref
Brian L. McClune, Todd DeFor, Claudio Brunstein, Rachel I. Vogel, Navneet S. Majhail, Veronika Bachanova, Linda J. Burns, Arne Slungaard & Daniel J. Weisdorf. (2012) Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. British Journal of Haematology 156:2, pages 273-275.
Crossref
Crossref
Jennifer R. Brown. (2011) The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia. Hematology 2011:1, pages 110-118.
Crossref
Crossref
William G. WierdaSwaminathan PadmanabhanGeoffrey W. ChanIra V. GuptaSteen Lisby & Anders Österborg. (2011) Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118:19, pages 5126-5129.
Crossref
Crossref
Kirsten FischerPaula CramerRaymonde BuschStephan StilgenbauerJasmin BahloCarmen D. SchweighoferSebastian BöttcherPeter StaibMichael KiehlMichael J. EckartGabriele KranzValentin GoedeThomas ElterAndreas BühlerDirk WinklerMichael KnebaHartmut DöhnerBarbara F. EichhorstMichael HallekClemens-Martin Wendtner. (2011) Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology 29:26, pages 3559-3566.
Crossref
Crossref
Luis Felipe Casado, José Antonio García Marco, Florinda Gilsanz, Marcos González, Eduardo Ríos, Javier de la Serna, Álvaro Urbano, Vicente Vicente, Carlos Rubio-Terrés & Antonio J. Castro. (2011) Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica. Gaceta Sanitaria 25:4, pages 274-281.
Crossref
Crossref
M. Steurer & S. Schmidt. (2011) ASH update 2010: Chronic lymphocytic leukaemia. memo - Magazine of European Medical Oncology 4:2, pages 117-119.
Crossref
Crossref
Matthew S. Kaufman, Angelica Caramanica, Dale Janson, Nancy Driscoll, Christina Johnson, Nina Kohn, Tarun Wasil & Kanti R. Rai. (2010) Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. Medical Oncology 28:2, pages 532-538.
Crossref
Crossref
Philip C. Amrein, Eyal C. Attar, Tak Takvorian, Ephraim P. Hochberg, Karen K. Ballen, Kathleen M. Leahy, David C. Fisher, Ann S. LaCasce, Eric D. Jacobsen, Philippe Armand, Robert P. Hasserjian, Lillian Werner, Donna Neuberg & Jennifer R. Brown. (2011) Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research 17:9, pages 2977-2986.
Crossref
Crossref
Hyo-jung Choi, Suk-yoon Song, Jae-bong Yoon, Li-kun Liu, Kristine Kim & Sang-hoon Cha. (2011) Isolation of human Fab antibodies specific for the low-affinity IgE receptor (CD23) by selecting a hierarchical antibody library system against B lymphoblastic IM-9 cells. Immunology Letters 136:2, pages 213-220.
Crossref
Crossref
Xavier C. Badoux, Michael J. Keating, Xuemei Wang, Susan M. O'Brien, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Susan Lerner, Hagop Kantarjian & William G. Wierda. (2011) Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117:11, pages 3016-3024.
Crossref
Crossref
Simon Hallam & John G. Gribben. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy
315
326
.
Karen W. L. Yee & Susan M. O'Brien. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies
81
102
.
David L. Porter, Edwin P. Alyea, Joseph H. Antin, Marcos DeLima, Eli Estey, J.H. Frederik Falkenburg, Nancy Hardy, Nicolaus Kroeger, Jose Leis, John Levine, David G. Maloney, Karl Peggs, Jacob M. Rowe, Alan S. Wayne, Sergio Giralt, Michael R. Bishop & Koen van Besien. (2010) NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 16:11, pages 1467-1503.
Crossref
Crossref
Susan O'Brien & Anders Österborg. (2010) Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 10:5, pages 361-368.
Crossref
Crossref
Constantine S. Tam & Michael J. Keating. (2010) Chemoimmunotherapy of chronic lymphocytic leukemia. Nature Reviews Clinical Oncology 7:9, pages 521-532.
Crossref
Crossref
Kumudha Balakrishnan, Dushyant Verma, Susan O'Brien, John Michael Kilpatrick, Yuling Chen, Brenita F. Tyler, Susan Bickel, Shanta Bantia, Michael J. Keating, Hagop Kantarjian, Varsha Gandhi & Farhad Ravandi. (2010) Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 116:6, pages 886-892.
Crossref
Crossref
Benigno C. Valdez & Borje S. Andersson. (2010) Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environmental and Molecular Mutagenesis 51:6, pages 659-668.
Crossref
Crossref
Arnon P. Kater & Sanne H. Tonino. (2010) Standards for the Treatment of Relapsed Chronic Lymphocytic Leukemia: A Case-Based Study. Clinical Lymphoma Myeloma and Leukemia 10, pages S34-S41.
Crossref
Crossref
William G. WierdaThomas J. KippsJiří MayerStephan StilgenbauerCathy D. WilliamsAndrzej HellmannTadeusz RobakRichard R. FurmanPeter HillmenMarek TrnenyMartin J.S. DyerSwami PadmanabhanMagdalena PiotrowskaTomas KozakGeoffrey ChanRandy DavisNedjad LosicJoris WilmsCharlotte A. RussellAnders Österborg. (2010) Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 28:10, pages 1749-1755.
Crossref
Crossref
Simon Hallam & John G. Gribben. (2010) Stem cell transplantation in chronic lymphocytic leukaemia – steering a safe course over shifting sands. Best Practice & Research Clinical Haematology 23:1, pages 109-119.
Crossref
Crossref
Leslie A. Andritsos, John C. Byrd & Steven M. Devine. 2010. Allogeneic Stem Cell Transplantation. Allogeneic Stem Cell Transplantation
43
52
.
Małgorzata Rogalińska, Jerzy Z. Błoński, Oxana Komina, Paweł Góralski, Jolanta D. Żołnierczyk, Henryk Piekarski, Tadeusz Robak, Zofia M. Kiliańska & Józefa Węsierska-Gądek. (2010) R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. Journal of Cellular Biochemistry 109:1, pages 217-235.
Crossref
Crossref
J. Delgado, S. Pillai, N. Phillips, S. Brunet, G. Pratt, J. Briones, R. Lovell, R. Martino, J. Ewing, A. Sureda, D.W. Milligan & J. Sierra. (2009) Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case–control retrospective analysis. Annals of Oncology 20:12, pages 2007-2012.
Crossref
Crossref
B Stamatopoulos, N Meuleman, C De Bruyn, P Mineur, P Martiat, D Bron & L Lagneaux. (2009) Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 23:12, pages 2281-2289.
Crossref
Crossref
Anne L. Angiolillo, Alice L. Yu, Gregory Reaman, Ashish M. Ingle, Rita Secola & Peter C. Adamson. (2009) A phase II study of Campath‐1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report. Pediatric Blood & Cancer 53:6, pages 978-983.
Crossref
Crossref
Thorsten ZenzSonja HäbeTina DenzelJulia MohrDirk WinklerAndreas BühlerAntonio SarnoSilja GronerDaniel MertensRaymonde Busch, Michael Hallek, Hartmut DöhnerStephan Stilgenbauer. (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:13, pages 2589-2597.
Crossref
Crossref
Julio DelgadoDonald W. Milligan & Peter Dreger. (2009) Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?. Blood 114:13, pages 2581-2588.
Crossref
Crossref
Simon Hallam & John G. Gribben. (2009) Transplantation in Chronic Lymphocytic Leukemia: Timing and Expectations. Clinical Lymphoma and Myeloma 9, pages S186-S193.
Crossref
Crossref
Julio Delgado, Javier Briones & Jorge Sierra. (2009) Emerging therapies for patients with advanced chronic lymphocytic leukaemia. Blood Reviews 23:5, pages 217-224.
Crossref
Crossref
Marina Motta, William G. Wierda & Alessandra Ferrajoli. (2009) Chronic lymphocytic leukemia. Cancer 115:17, pages 3830-3841.
Crossref
Crossref
Stephan StilgenbauerThorsten ZenzDirk WinklerAndreas BühlerRichard F. SchlenkSilja GronerRaymonde BuschManfred HenselUlrich DührsenJürgen FinkePeter DregerUlrich JägerEva LengfelderKarin HohlochUlrike SölingRudolf SchlagMichael KnebaMichael HallekHartmut Döhner. (2009) Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology 27:24, pages 3994-4001.
Crossref
Crossref
Apostolia-Maria Tsimberidou & Michael J. Keating. (2009) Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 115:13, pages 2824-2836.
Crossref
Crossref
Sonia Cunningham, Sabeeha Muneer, Sundar Jagannath, Sagar Lonial, Stefan Faderl & Stephan Stilgenbauer. (2009) The 50th Annual Meeting of the American Society of Hematology. Clinical Lymphoma and Myeloma 9:3, pages 197-205.
Crossref
Crossref
Constantine S. Tam & Issa Khouri. (2009) The role of stem cell transplantation in the management of chronic lymphocytic leukaemia. Hematological Oncology 27:2, pages 53-60.
Crossref
Crossref
Tahamtan Ahmadi, Tapan Maniar, Stephen Schuster & Edward Stadtmauer. (2009) Chronic Lymphocytic Leukemia: New Concepts and Emerging Therapies. Current Treatment Options in Oncology 10:1-2, pages 16-32.
Crossref
Crossref
John G. Gribben & Michael Hallek. (2009) Rediscovering alemtuzumab: current and emerging therapeutic roles. British Journal of Haematology 144:6, pages 818-831.
Crossref
Crossref
Rifca Le Dieu & John G Gribben. 2009. Hematopoietic Stem Cell Transplantation in Clinical Practice. Hematopoietic Stem Cell Transplantation in Clinical Practice
105
112
.
Matt Kalaycio. (2008) Clinical Experience with Bendamustine: A New Treatment for Patients with Chronic Lymphocytic Leukemia. Clinical Leukemia 2:4, pages 223-229.
Crossref
Crossref
Julio Delgado, Srinivas Pillai, Reuben Benjamin, Dolores Caballero, Rodrigo Martino, Amit Nathwani, Richard Lovell, Kirsty Thomson, Jose A. Perez-Simon, Anna Sureda, Panagiotis Kottaridis, Lourdes Vazquez, Karl Peggs, Jorge Sierra, Donald Milligan & Stephen Mackinnon. (2008) The Effect of In Vivo T Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation 14:11, pages 1288-1297.
Crossref
Crossref
Elias Anaissie. 2008. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia
261
292
.
John Byrd, Farrukh Awan, Thomas Lin & Michael Grever. 2008. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia
165
184
.
Karen Yee, Michael Keating & Susan O’Brien. 2008. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia
141
164
.
John G. Gribben. (2008) Role of Allogeneic Hematopoietic Stem-Cell Transplantation in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 26:30, pages 4864-4865.
Crossref
Crossref
Mohamed L. Sorror, Barry E. Storer, Brenda M. Sandmaier, Michael Maris, Judith Shizuru, Richard Maziarz, Edward Agura, Thomas R. Chauncey, Michael A. Pulsipher, Peter A. McSweeney, James C. Wade, Benedetto Bruno, Amelia Langston, Jerald Radich, Dietger Niederwieser, Karl G. Blume, Rainer Storb & David G. Maloney. (2008) Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. Journal of Clinical Oncology 26:30, pages 4912-4920.
Crossref
Crossref
Maija Itälä, Anna-Riina Huhtinen, Vesa Juvonen, Veli Kairisto, Tarja-Terttu Pelliniemi, Tarja-Leena Penttilä, Auvo Rauhala, Anri Tienhaara & Kari Remes. (2008) Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR. European Journal of Haematology 81:2, pages 100-106.
Crossref
Crossref
Francis A. Ayuk, Nabil Atassi, Gunther Schuch, Sormeh Mina, Lubin Fang, Carsten Bokemeyer, Boris Fehse, Axel R. Zander & Nicolaus Kröger. (2008) Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia. Leukemia Research 32:8, pages 1200-1206.
Crossref
Crossref
Alessandra Ferrajoli, Bang-Ning Lee, Ellen J. Schlette, Susan M. O'Brien, Hui Gao, Sijin Wen, William G. Wierda, Zeev Estrov, Stefan Faderl, Evan N. Cohen, Changping Li, James M. Reuben & Michael J. Keating. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:11, pages 5291-5297.
Crossref
Crossref
Alessandra Ferrajoli, William G. Wierda, Ruth LaPushin, Susan M. O’Brien, Stefan Faderl, Mary L. Browning & Michael J. Keating. (2008) Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. European Journal of Haematology 80:4, pages 296-298.
Crossref
Crossref
Varsha Gandhi, Constantine Tam, Susan O'Brien, Roxanne C. Jewell, Carlos O. RodriguezJrJr, Susan Lerner, William Plunkett & Michael J. Keating. (2008) Phase I Trial of Nelarabine in Indolent Leukemias. Journal of Clinical Oncology 26:7, pages 1098-1105.
Crossref
Crossref
Rifca Le Dieu & John G. Gribben. 2008. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cell Transplantation
137
147
.
Rebecca L. Auer, John Gribben & Finbarr E. Cotter. (2007) Emerging therapy for chronic lymphocytic leukaemia. British Journal of Haematology 139:5, pages 635-644.
Crossref
Crossref
Constantine S. Tam & Michael J. Keating. (2007) Chemoimmunotherapy of chronic lymphocytic leukemia. Best Practice & Research Clinical Haematology 20:3, pages 479-498.
Crossref
Crossref
John C. Byrd, Susan O'Brien, Ian W. Flinn, Thomas J. Kipps, Mark Weiss, Kanti Rai, Thomas S. Lin, James Woodworth, Dee Wynne, Jennifer Reid, Arturo Molina, Bryan Leigh & Sarah Harris. (2007) Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research 13:15, pages 4448-4455.
Crossref
Crossref
Aristeidis Chaidos, Ed Kanfer & Jane F. Apperley. (2007) Risk assessment in haemotopoietic stem cell transplantation: Disease and disease stage. Best Practice & Research Clinical Haematology 20:2, pages 125-154.
Crossref
Crossref
Danelle F JamesThomas J Kipps. (2007) Alemtuzumab in chronic lymphocytic leukemia. Future Oncology 3:1, pages 29-42.
Crossref
Crossref
Rifca Le Dieu & John G. Gribben. (2007) Transplantation in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports 2:1, pages 56-63.
Crossref
Crossref
Thomas Elter, Andreas Engert & Michael Hallek. 2007. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
733
777
.
Neil E. KaySusan M. GeyerTimothy G. CallTait D. ShanafeltClive S. ZentDiane F. JelinekRenee TschumperNancy D. BoneGordon W. DewaldThomas S. Lin, Nyla A. Heerema, Lisa Smith, Michael R. Grever & John C. Byrd. (2006) Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:2, pages 405-411.
Crossref
Crossref
W Guy Scott & Helen M Scott. (2007) Economic Evaluation of Third-Line Treatment with Alemtuzumab for Chronic Lymphocytic Leukaemia. Clinical Drug Investigation 27:11, pages 755-764.
Crossref
Crossref
P Dreger, P Corradini, E Kimby, M Michallet, D Milligan, J Schetelig, W Wiktor-Jedrzejczak, D Niederwieser, M Hallek & E Montserrat. (2006) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21:1, pages 12-17.
Crossref
Crossref
Michael Fiegl, Andreas Falkner, Georg Hopfinger, Stefan Brugger, August Zabernigg, Franz Bauer, Ferdinand Haslbauer, Dita Demirtas, Peter Grossschmidt, Georg Tatzreiter, Günther Gastl & Richard Greil. (2006) Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia. Cancer 107:10, pages 2408-2416.
Crossref
Crossref
Abeer N. AbouYabis & Christopher R. Flowers. (2006) Treatment Options for Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. Clinical Leukemia 1:1, pages 46-56.
Crossref
Crossref
Karen W.L. Yee & Susan M. O'Brien. (2006) Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clinic Proceedings 81:8, pages 1105-1129.
Crossref
Crossref
Carl R. Willis, Amy Goodrich, Kathy Park, Jamie K. Waselenko, Margaret Lucas, Amy Reese, Louis F. Diehl, Michael R. Grever, John C. Byrd & Ian W. Flinn. (2006) A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Annals of Hematology 85:5, pages 301-307.
Crossref
Crossref
Peter Hillmen. (2006) Beyond Detectable Minimal Residual Disease in Chronic Lymphocytic Leukemia. Seminars in Oncology 33, pages 23-28.
Crossref
Crossref
Kanti R. Rai. (2006) Novel Therapeutic Strategies With Alemtuzumab for Chronic Lymphocytic Leukemia. Seminars in Oncology 33, pages 15-22.
Crossref
Crossref
Julio DelgadoKirsty ThomsonNigel RussellJoanne EwingWendy StewartGordon CookStephen DevereuxRichard LovellRajesh ChopraDavid I. MarksStephen MackinnonDonald W. Milligan. (2006) Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 107:4, pages 1724-1730.
Crossref
Crossref
Emili MontserratCarol MorenoJordi EsteveAlvaro Urbano-IspizuaEva GinéFrancesc Bosch. (2006) How I treat refractory CLL. Blood 107:4, pages 1276-1283.
Crossref
Crossref
Thomas S. Lin & John C. Byrd. 2006. Oncology. Oncology
1210
1228
.
S Faderl, S Coutré, J C Byrd, C Dearden, A Denes, M J S Dyer, S A Gregory, J G Gribben, P Hillmen, M Keating, S Rosen, P Venugopal & K Rai. (2005) The evolving role of Alemtuzumab in management of patients with CLL. Leukemia 19:12, pages 2147-2152.
Crossref
Crossref
Thomas Elter, Peter Borchmann, Holger Schulz, Marcel Reiser, Sven Trelle, Roland Schnell, Markus Jensen, Peter Staib, Timo Schinköthe, Hartmut Stützer, Jürgen Rech, Martin Gramatzki, Walter Aulitzky, Ibrahim Hasan, Andreas Josting, Michael Hallek & Andreas Engert. (2005) Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial. Journal of Clinical Oncology 23:28, pages 7024-7031.
Crossref
Crossref
Farhad Ravandi & Susan O’Brien. (2005) Infections associated with purine analogs and monoclonal antibodies. Blood Reviews 19:5, pages 253-273.
Crossref
Crossref
John G. Gribben. (2005) Salvage Therapy for CLL and the Role of Stem Cell Transplantation. Hematology 2005:1, pages 292-298.
Crossref
Crossref
D. Oscier, C. Fegan, P. Hillmen, T. Illidge, S. Johnson, P. Maguire, E. Matutes & D. Milligan. (2004) Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. British Journal of Haematology 125:3, pages 294-317.
Crossref
Crossref
Michael Keating, Stephen Coutré, Kanti Rai, Anders Österborg, Stefan Faderl, Ben Kennedy, Tom Kipps, Gerald Bodey, John C. Byrd, Steven Rosen, Claire Dearden, Martin J.S. Dyer & Peter Hillmen. (2004) Management Guidelines for Use of Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma 4:4, pages 220-227.
Crossref
Crossref
John C. Byrd, Stephan Stilgenbauer & Ian W. Flinn. (2004) Chronic Lymphocytic Leukemia. Hematology 2004:1, pages 163-183.
Crossref
Crossref
Alessandra Ferrajoli, Susan M. O'Brien, Jorge E. Cortes, Francis J. Giles, Deborah A. Thomas, Stefan Faderl, Razelle Kurzrock, Susan Lerner, Dimitrios P. Kontoyiannis & Michael J. Keating. (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98:4, pages 773-778.
Crossref
Crossref
. (2003) Current Awareness in Hematological Oncology. Hematological Oncology 21:1, pages 43-50.
Crossref
Crossref
James E Frampton & Antona J Wagstaff. (2003) Alemtuzumab. Drugs 63:12, pages 1229-1243.
Crossref
Crossref
Susan N. O’Brien, Nicole M.A. Blijlevens, Tahsine H. Mahfouz & Elias J. Anaissie. (2003) Infections in Patients with Hematological Cancer: Recent Developments. Hematology 2003:1, pages 438-472.
Crossref
Crossref